Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALXO

Alx Oncology Holdings Inc

Sep 15 • 04:00PM ET

1.05

-0.01 -0.94 %

Healthcare • Biotechnology • USA • NASD

Peers: IOVA KPTI SRRK XNCR TVRD AFMD TGTX BHVN ZLAB BPMC

| Held by: VTI VXF SCHA VHT BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.20	Insider Own	30.19%	Shs Outstand	53.51M	Perf Week	-5.41%
Market Cap	56.23M	Forward P/E	-	EPS next Y	-0.95	Insider Trans	0.43%	Shs Float	37.38M	Perf Month	60.31%
Enterprise Value	-6.90M	PEG	-	EPS next Q	-0.33	Inst Own	36.21%	Short Float	4.86%	Perf Quarter	104.92%
Income	-116.57M	P/S	-	EPS this Y	38.72%	Inst Trans	-27.08%	Short Ratio	1.98	Perf Half Y	26.49%
Sales	0.00M	P/B	0.87	EPS next Y	39.93%	ROA	-75.22%	Short Interest	1.82M	Perf YTD	-37.13%
Book/sh	1.20	P/C	0.71	EPS next 5Y	32.45%	ROE	-104.21%	52W High	2.36 -55.51%	Perf Year	-51.83%
Cash/sh	1.48	P/FCF	-	EPS past 3/5Y	-7.67% -32.29%	ROIC	-154.31%	52W Low	0.40 159.90%	Perf 3Y	-92.28%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.79% 14.71%	Perf 5Y	-97.60%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	39.60%	Oper. Margin	-	ATR (14)	0.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.52	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.14	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	4.52	EPS Q/Q	36.13%	SMA20	-2.83%	Beta	1.11	Target Price	2.00
Payout	-	Debt/Eq	0.25	Sales Q/Q	-	SMA50	36.94%	Rel Volume	0.20	Prev Close	1.06
Employees	80	LT Debt/Eq	0.17	Earnings	Aug 12 AMC	SMA200	14.49%	Avg Volume	918.96K	Price	1.05
IPO	Jul 17, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-16.11% -	Trades		Volume	185,872	Change	-0.94%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-06-25	Upgrade	Jefferies	Hold → Buy	$2 → $3
Dec-19-24	Downgrade	Jefferies	Buy → Hold	$12 → $2
Mar-08-24	Downgrade	Stifel	Buy → Hold	$10 → $14
Dec-08-23	Upgrade	Jefferies	Hold → Buy	$8 → $18
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$65 → $25
Sep-30-21	Initiated	Stifel	Buy	$106
May-05-21	Resumed	Credit Suisse	Outperform	$98
Apr-26-21	Resumed	Credit Suisse	Outperform	$98
Apr-06-21	Initiated	UBS	Buy
Feb-10-21	Initiated	H.C. Wainwright	Buy	$100
Aug-11-20	Initiated	Piper Sandler	Overweight	$55
Aug-11-20	Initiated	Jefferies	Buy	$50
Aug-11-20	Initiated	Credit Suisse	Outperform	$53
Aug-11-20	Initiated	Cantor Fitzgerald	Overweight	$64

Show Previous Ratings

Sep-12-25 08:30AM	ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer (GlobeNewswire) -10.17%
Aug-29-25 12:00PM	ALX Oncology to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-19-25 08:00AM	ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors (GlobeNewswire) -8.37%
Aug-13-25 03:13AM	ALX Oncology Holdings Inc (ALXO) Q2 2025 Earnings Call Highlights: Promising Trial Results and ... (GuruFocus.com) +7.40%
Aug-12-25 04:05PM	ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Loading…
Aug-05-25 08:00AM	ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire) +12.68%
May-30-25 08:00AM	ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference (GlobeNewswire)
May-20-25 08:00AM	ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event (GlobeNewswire)
May-13-25 08:00AM	ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 (GlobeNewswire) +10.52%
May-08-25 08:30AM	ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-25 08:00AM	ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-28-25 07:51AM	ALX Oncologys CD47-blocker and Keytruda combo fails in two Phase II trials (Clinical Trials Arena)
Apr-25-25 01:10PM	ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma (GlobeNewswire) -9.87%
09:00AM	ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints (GlobeNewswire)
Apr-07-25 08:00AM	ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate (GlobeNewswire)
09:55AM	Loading…
Mar-20-25 09:55AM	ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Mar-07-25 01:27PM	Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday (Insider Monkey) -19.08%
Mar-06-25 04:01PM	ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +25.96%
Mar-05-25 08:00AM	ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event (GlobeNewswire)
Feb-27-25 08:00AM	ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (GlobeNewswire)
Feb-18-25 08:00AM	ALX Oncology to Host Virtual R&D Day on March 5, 2025 (GlobeNewswire) +7.27%
Jan-23-25 02:44PM	ALX Oncology Shares Drop 15% Following Positive Phase 2 (GuruFocus.com) -9.44%
08:00AM	ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer (GlobeNewswire)
Jan-22-25 04:01PM	ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules (GlobeNewswire) +9.09%
09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
08:00AM	ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors (GlobeNewswire)
Jan-21-25 05:00PM	ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI (GlobeNewswire) -5.17%
Jan-07-25 09:40AM	Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:57AM	Loading…
Dec-19-24 08:57AM	Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold' (Investing.com) -19.57%
Dec-18-24 08:00AM	ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Dec-12-24 08:00AM	ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 (GlobeNewswire) -5.96%
Dec-10-24 09:00AM	ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer (GlobeNewswire) -8.14%
Nov-26-24 08:00AM	ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-21-24 09:35AM	ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +6.61%
Nov-14-24 08:00AM	ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-07-24 04:00PM	ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-24 08:00AM	ALX Oncology Announces November Investor Conference Participation (GlobeNewswire)
Nov-01-24 05:30PM	ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 (GlobeNewswire)
Oct-10-24 07:04PM	Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc (GuruFocus.com) -11.11% +6.94%
Sep-09-24 08:00AM	ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) +9.95%
Sep-04-24 08:00AM	ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi (GlobeNewswire)
Aug-08-24 04:05PM	ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-06-24 04:01PM	ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors (GlobeNewswire) -6.55%
Aug-01-24 09:05AM	Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients (Benzinga) -41.67%
06:52AM	ALX Oncologys evorpacept shows potential in Phase II gastric cancer trial (Clinical Trials Arena)
Jul-31-24 04:01PM	ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer (GlobeNewswire) -11.93%
05:30AM	ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Jun-17-24 11:00AM	Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO) (GuruFocus.com) -8.32%
Jun-03-24 09:35AM	Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround (Zacks) -15.71%
Jun-02-24 10:00AM	ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer (GlobeNewswire)
May-29-24 09:00AM	ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference (GlobeNewswire) -10.91%
May-16-24 02:54AM	Insider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells Shares (GuruFocus.com)
May-14-24 09:55AM	Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet (Zacks)
May-10-24 02:21PM	ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ... (GuruFocus.com)
May-09-24 10:57PM	ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024 (InvestorPlace)
04:00PM	ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 05:38PM	Alx Oncology Holdings Insider Sold Shares Worth $318,334, According to a Recent SEC Filing (MT Newswires) -5.41%
May-07-24 09:00AM	ALX Oncology Appoints Allison Dillon as Chief Business Officer (GlobeNewswire) +11.28%
Apr-30-24 09:00AM	ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer (GlobeNewswire)
Apr-24-24 10:00AM	ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-11-24 09:30AM	ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study (Zacks) +11.04%
Apr-09-24 05:30PM	ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma ( R/R B-NHL ) (GlobeNewswire)
Apr-06-24 01:33AM	ALX Oncology Holdings Inc (ALXO) Insider Sells Shares (GuruFocus.com)
Mar-08-24 03:48PM	ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer (Benzinga) -6.34%
Mar-07-24 10:53PM	ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q4 2023 (InvestorPlace) +9.95%
10:41PM	ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending (GuruFocus.com)
04:03PM	ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 04:30PM	ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting (GlobeNewswire)
Jan-03-24 08:00AM	ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-23 04:21PM	7 Small-Cap Stocks That Wall Street Loves for Good Reason (InvestorPlace) +18.04%
Nov-13-23 04:47PM	ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com) +8.08%
04:05PM	ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-23 04:05PM	ALX Oncology Announces November Investor Conference Participation (GlobeNewswire) +6.35%
Oct-10-23 04:05PM	ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +16.24%
Oct-06-23 04:59AM	The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna (Zacks) +27.38%
Oct-05-23 10:58AM	Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More (Zacks)
08:00AM	ALX Oncology Announces Pricing of Public Offering (GlobeNewswire)
Oct-04-23 04:10PM	ALX Oncology Announces Proposed Public Offering (GlobeNewswire) -15.05%
11:39AM	ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data (Zacks)
Oct-03-23 11:15AM	Why ALX Oncology Stock Is Skyrocketing Today (Motley Fool) +56.13%
09:36AM	Midday movers: McCormick Airbnb, Point Biopharma and more (Investing.com)
06:00AM	ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Oct-02-23 04:05PM	ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Sep-06-23 08:00AM	ALX Oncology Realigns Executive Leadership Team (GlobeNewswire) +6.37%
Aug-31-23 07:00AM	ALX Oncology Announces September Investor Conference Participation (GlobeNewswire)
Aug-14-23 07:31PM	While dollars continue to flow into biotech, companies cut more jobs (American City Business Journals)
Aug-10-23 04:01PM	ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update (GlobeNewswire)
09:55AM	ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jun-26-23 07:00AM	ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer (GlobeNewswire)
May-11-23 04:01PM	ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
May-09-23 07:00AM	ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer (GlobeNewswire) +6.36%
Apr-25-23 07:00AM	ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma (GlobeNewswire)
Apr-19-23 11:36AM	These 2 Strong Buy Penny Stocks Could Rally to $40 (or More), Says Piper Sandler (TipRanks) +6.44%
Mar-14-23 08:00AM	ALX Oncology and Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer (PR Newswire) -6.75%
Mar-13-23 07:00AM	ALX Oncology and Quantum Leap Healthcare Collaborative Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer (GlobeNewswire)
Mar-09-23 04:01PM	ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones (GlobeNewswire) -5.93% -8.18%
Feb-16-23 07:00AM	ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer (GlobeNewswire)
Jan-05-23 07:00AM	ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023 (GlobeNewswire)

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shantharam Harish	Chief Financial Officer	Aug 18 '25	Buy	0.78	75,000	58,402	75,000	Aug 20 04:02 PM
Pinto Shelly	SVP, FINANCE AND CAO	Aug 15 '25	Sale	0.64	611	391	89,198	Aug 19 04:12 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Aug 15 '25	Sale	0.64	2,382	1,525	212,888	Aug 19 04:09 PM
Pinto Shelly	SVP, FINANCE AND CAO	Jul 07 '25	Sale	0.45	2,011	905	86,809	Jul 08 04:37 PM
Pinto Shelly	SVP, FINANCE AND CAO	Jun 30 '25	Sale	0.43	1,532	659	88,820	Jul 01 04:22 PM
Pinto Shelly	SVP, FINANCE AND CAO	Feb 19 '25	Sale	1.15	550	633	87,352	Feb 21 04:25 PM
Pons Jaume	PRESIDENT & CSO	Feb 19 '25	Sale	1.15	1,326	1,525	579,388	Feb 21 04:23 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Feb 19 '25	Sale	1.15	2,159	2,483	170,270	Feb 21 04:20 PM
Pinto Shelly	Interim CFO	Jan 06 '25	Sale	1.80	2,221	3,998	87,902	Jan 08 04:10 PM
Pinto Shelly	Interim CFO	Dec 30 '24	Sale	1.58	1,426	2,253	90,123	Jan 02 04:46 PM
Pons Jaume	PRESIDENT & CSO	Dec 30 '24	Sale	1.58	10,796	17,060	580,714	Jan 02 04:43 PM
Hemrajani Rekha	Director	Dec 02 '24	Buy	1.55	30,000	46,404	33,000	Dec 04 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALXO

Alx Oncology Holdings Inc

Upgrade your FINVIZ experience